Flaccid Brachial Monoplegia As Initial Presentation in a Patient With Progressive Multifocal Leukoencephalopathy

Lisa B Shields1, Vasudeva G Iyer2, Hilary A Highfield3

  • 1Neurological Surgery, Norton Neuroscience Institute, Norton Healthcare, Louisville, USA.

Cureus
|May 23, 2022
PubMed

Insights

Progressive multifocal leukoencephalopathy (PML) can present atypically, even in non-immunocompromised individuals. This case highlights the importance of brain biopsy for diagnosing PML when cerebrospinal fluid tests are negative.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Oncology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, fatal demyelinating disease.
  • PML is caused by John Cunningham virus (JCV) reactivation in immunocompromised individuals.
  • Diagnosis typically involves JCV DNA detection in cerebrospinal fluid (CSF) via PCR, alongside clinical and imaging findings.

Observation:

  • A patient presented with rapid right upper extremity weakness, suggesting subcortical conduction block.
  • The patient had no prior history of immunocompromise.
  • The patient was diagnosed with atypical small cell lymphocytic lymphoma without chemotherapy or monoclonal antibody treatment.

Findings:

  • Cerebrospinal fluid (CSF) testing for JCV DNA via PCR was negative.
  • PML was ultimately confirmed through brain biopsy.
  • This case represents an uncommon clinical presentation of PML.

Implications:

  • Highlights the potential for false-negative JCV PCR results in CSF.
  • Underscores the necessity of brain biopsy for definitive PML diagnosis in ambiguous cases.
  • Emphasizes the need for a high index of suspicion for PML, even in the absence of overt immunocompromise.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.4K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
42
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
738